More Waves to come on stereopure antisense oligo tech

Though the first clinical readouts from Wave’s antisense oligo platform disappointed investors, the company thinks it can parlay the learnings into improved efficacy. 2020 will offer more data readouts to support or refute the company’s hypothesis that stereopure oligos will have better efficacy and safety than the standard oligo format, which involves random mixtures of molecules with identical sequences, but different 3D conformations.

The next chances to make the case will come from a higher dose and a second version of its Huntington disease therapy, both of which target the mutant version of the huntingtin protein (HTT)...